- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02834533
Role of Virtual Reality in MS Rehabilitation
Robotic Gait Training in Multiple Sclerosis: a Randomized Clinical Trial Evaluating Virtual Reality Role
Objective: To investigate the role of virtual reality (VR) paired with robotic-assisted gait training (RAGT) compared with RAGT alone in patients with Multiple Sclerosis (MS).
Method: A Randomized, double-blind, controlled clinical trial was carried out in forty patients with relapsing remitting MS. All patients were randomized into two groups. One group practiced Lokomat without VR (group G1), the other one the Lokomat with VR (G2). Both the groups performed 40-1h-training sessions by Lokomat (for 3 times a week). A skilled-blinded neurologist and psychologist administered clinical and neuropsychological scales. All the clinical tests were performed at the beginning (T0) and at the end (T1) of the rehabilitative program.
Study Overview
Detailed Description
METHODS The present study is a single-blind randomized trial, conducted according to the Declaration of Helsinki, the guidelines for Good Clinical Practice, and the (CONSORT) Statement guidelines. The study protocol was approved by our Institutional Review Board and Ethics Committee (project number: 24/2013).
One hundred and fifty consecutive outpatients with relapsing-remitting multiple sclerosis and gait and/or balance disturbance, attending the Laboratory of Robotic Neurorehabilitation of the IRCCS Neurolesi Bonino-Pulejo (Messina, Italy) from January 2015 to January 2016, were invited to participate in the study, and were screened for study eligibility.
Inclusion/exclusion criteria Inclusion criteria were: age 30-65 years; severe walking disability with Expanded Disability Status Score between 3.5 and 6.0 (Piramidal subitem ≥3); Montreal Cognitive Assessment score ≥24; absence of concomitant neurological or orthopedic conditions that may interfere with ambulation; stable pharmacological therapy for at least 6 months. Exclusion criteria were: multiple sclerosis relapse during the three months prior to recruitment; presence of paroxysmal vertigo; lower limb botulinum toxin injections within the previous 12 weeks; cardiorespiratory instability; high-risk of spontaneous fracture; lower-limb skin lesions and phlebitis/thrombosis; more than 130 kg body weight.
Randomization Forty out of 150 outpatients with relapsing remitting multiple sclerosis form, according to Polman criteria14 selected between January 2015-2016, were enrolled and randomized and allocated into either Group1 (G1 i.e. Lokomat-Nanos) or Group2 (G2 i.e. Lokomat-Pro), as shown in fig 1. The subjects were randomly assigned to one of two treatment groups, using a simple randomization scheme generated by a software (www.randomization.com). Individual, sequentially numbered index cards with the random assignments were prepared. The index cards were folded and placed in sealed opaque envelopes. A physician member of the research team, who was blinded to the baseline examination findings, opened the envelopes to attribute the interventions according to the group assignments.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Severe walking disability with Expanded Disability Status Score (EDSS) between 3.5 and 6.0 (Pyramidal subitem ≥3)
- Montreal Cognitive Assessment score ≥24
- Absence of concomitant neurological or orthopedic conditions that may interfere with ambulation.
Exclusion Criteria:
- MS relapse during the three months prior to recruitment
- Not well defined pharmacological therapy; presence of paroxysmal vertigo
- Lower limb botulinum toxin injections within the previous 12 weeks
- Cardiorespiratory instability high-risk of spontaneous fracture
- Lower-limb skin lesions and phlebitis/thrombosis
- More than 130kg body weight
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: column heading in tables.
The group 1 (G1, n=20) underwent Lokomat-Nanos training.
Each patient underwent 40 1h-training sessions (for 3 times a week).
Both the study groups were treated by Lokomat (Hocoma Inc., Zurich, Switzerland), which includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint .
The overall duration of Lokomat therapy, including the time to get on and off, was 60min, while the robotic gait training lasted around 40min.
|
Lokomat (Hocoma Inc., Zurich, Switzerland)includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint .
As compared to Lokomat-Nanos, the Pro device offers a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
|
Active Comparator: row and column in table
The group 2 (G2, n=20) underwent Lokomat-Pro training, with the same G1 sessions.
The Pro device offers instead a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
|
Lokomat (Hocoma Inc., Zurich, Switzerland)includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint .
As compared to Lokomat-Nanos, the Pro device offers a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Berg Balance Scale
Time Frame: Up to 14 weeks
|
BBS is a clinical scale to evaluate balance
|
Up to 14 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Coping Orientation to Problem Experienced
Time Frame: Up to 14 weeks
|
The test is aimed at evaluating how a person deals with a specific problem, with two main coping strategies, i.e. adaptation and avoidance.
|
Up to 14 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 24/2014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis Relapse
-
AB ScienceCompletedMultiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Relapse FreePoland, Spain, Bulgaria, France, Germany, Greece, Romania
-
Marmara UniversityCompletedMultiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis RelapseTurkey
-
Kuopio University HospitalCompletedRelapse-remitting Multiple SclerosisFinland
-
University of AthensRecruiting
-
Novartis PharmaceuticalsTerminatedRelapse Remitting Multiple SclerosisUnited States, Ukraine, Czechia
-
Thomas Jefferson UniversityRecruitingRelapse Remitting Multiple SclerosisUnited States
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Dr. Luanne MetzMultiple Sclerosis Society of CanadaCompletedClinically Isolated Syndromes | Early Single Relapse of Multiple SclerosisCanada
-
Universidad Nacional Autonoma de MexicoInstituto Nacional de Neurología y NeurocirugíaEnrolling by invitationMethylprednisolone | Intranasal Administration | Patients With an Active Multiple Sclerosis RelapseMexico
-
Regina Elena Cancer InstituteIcahn School of Medicine at Mount Sinai; University of Roma La SapienzaUnknownMultiple Sclerosis | RelapseUnited States, Italy
Clinical Trials on Lokomat
-
IRCCS Eugenio MedeaNational Research Council of ItalyUnknownTraumatic Brain InjuryItaly
-
Instituto Nacional de RehabilitacionNational Council of Science and Technology, MexicoCompleted
-
Holland Bloorview Kids Rehabilitation HospitalCIBC Children's FoundationCompleted
-
University of AarhusCompleted
-
US Department of Veterans AffairsUniversity of Maryland; Kernan Orthopaedics and Rehabilitation HospitalCompletedSpinal Cord Injury | Tetraplegia | Quadriplegia | ParaplegiaUnited States
-
US Department of Veterans AffairsTerminated
-
IRCCS Eugenio MedeaCompletedCerebral Palsy | Acquired Brain Injury | Hereditary Spastic ParaplegiaItaly
-
IRCCS Centro Neurolesi "Bonino-Pulejo"Completed
-
Holland Bloorview Kids Rehabilitation HospitalUnknown
-
US Department of Veterans AffairsCompletedParkinson's DiseaseUnited States